Early intervention with recombinant factor VIIa in severe postpartum hemorrhage: a retrospective observational study for evaluation of safety and efficacy of recombinant activated factor VII

Priyanka Shahi; Amrita Pritam; Anjana Sinha; Pratima; Geeta Sinha; Kumari Bibha; Zaheen Fatma

doi:10.18203/2320-1770.ijrcog20252173

Authors

Priyanka Shahi Department of Gynaecology and Obstetrics, Patna Medical College and Hospital, Patna, Bihar, India
Amrita Pritam Department of Gynaecology and Obstetrics, Sri Krishna Medical College and Hospital, Muzaffarpur, Bihar, India
Anjana Sinha Department of Gynaecology and Obstetrics, Patna Medical College and Hospital, Patna, Bihar, India
Pratima Department of Gynaecology and Obstetrics, Sri Krishna Medical College and Hospital, Muzaffarpur, Bihar, India
Geeta Sinha Department of Gynaecology and Obstetrics, Patna Medical College and Hospital, Patna, Bihar, India
Kumari Bibha Department of Gynaecology and Obstetrics, Sri Krishna Medical College and Hospital, Muzaffarpur, Bihar, India
Zaheen Fatma Department of Gynaecology and Obstetrics, Patna Medical College and Hospital, Patna, Bihar, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20252173

Keywords:

Postpartum hemorrhage, rFVIIa, Blood loss, Invasive procedures

Abstract

Background: Postpartum hemorrhage (PPH) is a critical obstetric emergency and leading cause of maternal death worldwide and in India. Despite the availability of several measures to treat PPH, maternal mortality from severe PPH remains high, highlighting the unmet need in the management of PPH. One promising development is the use of recombinant activated factor VII (rFVIIa), which has been recently approved for treatment of severe PPH in India.

Methods: This retrospective observational study compared the requirement of blood products, requirement of invasive procedures, and blood loss before and after rFVIIa administration in patients of severe PPH from two tertiary care centres in Bihar. rFVIIa was given when there was a persistent bleeding (blood loss>1000 ml) post-sequential uterotonics administration.

Results: Only one of 47 patients with severe PPH required an invasive procedure after receiving rFVIIa; the remaining 46 responded without needing further surgical intervention. rFVIIa administration resulted in a significant reduction in blood loss, from 1215 ml pre-administration to only 219 ml post-administration (p<0.001). rFVIIa administration also resulted in a significant reduction in requirement of blood products, from 3.67 units pre-administration to only 1.44 units post-administration (n=34) (p<0.0001). No Thromboembolic events were reported in 30 days of follow-up.

Conclusions: The study demonstrated that early use of rFVIIa in patients with severe PPH significantly reduced blood loss, blood product requirements, and the need for invasive procedures to control bleeding. When administered early in the management of severe PPH, rFVIIa offers a rapid, non-invasive, lifesaving, and fertility-preserving treatment option.

Metrics

Metrics Loading ...

References

WHO. Postpartum haemorrhage. 2024. Available at: https://www.who.int/teams/sexual-and-reproductive-health-and-research-(srh)/areas-of-work/maternal-and-perinatal-health/postpartum-haemorrhage. Accessed on 20 January 2025.

Patel M. Postpartum Hemorrhage: Enhancing Outcomes for Mothers by Effective Management. J Obstet Gynecol India. 2024;74(3):191-5. DOI: https://doi.org/10.1007/s13224-024-02022-3

WHO. A roadmap to combat postpartum haemorrhage between 2023 and 2030. 2024. Available at: https://www.who.int/publications/i/item/9789240081802. Accessed on 20 January 2025.

WHO. Maternal mortality. World Health Organization. 2024. Available at: https://www.who. int/news-room/fact-sheets/detail/maternal-mortality. Accessed on 20 January 2025.

Say L, Chou D, Gemmill A, Tunçalp Ö, Moller AB, Daniels J, et al. Global causes of maternal death: a WHO systematic analysis. The Lancet Global Health. 2014;2(6):e323-33. DOI: https://doi.org/10.1016/S2214-109X(14)70227-X

Meh C, Sharma A, Ram U, Fadel S, Correa N, Snelgrove J, et al. Trends in maternal mortality in India over two decades in nationally representative surveys. BJOG. 2022;129(4):550-61. DOI: https://doi.org/10.1111/1471-0528.16888

FIGO, ICM. International Federation of Gynecology and Obstetrics (FIGO) and The International Confederation of Midwives (ICM): Joint statement of recommendation for the use of tranexamic acid for the treatment of postpartum haemorrhage. 2021. Available at: https://www.figo.org/joint-statement-recommendation-tranexamic-acid-treatment-pph. Accessed on 20 January 2025.

Surbek D, Blatný J, Wielgos M, Acs N, Edwards H, Erez O, et al. Role of recombinant factor VIIa in the clinical management of severe postpartum hemorrhage: consensus among European experts. J Matern Fetal Neonatal Med. 2024;37(1):2332794. DOI: https://doi.org/10.1080/14767058.2024.2332794

Escobar MF, Nassar AH, Theron G, Barnea ER, Nicholson W, Ramasauskaite D, et al. FIGO recommendations on the management of postpartum hemorrhage 2022. Int J Gynecol Obstetr. 2022;157(S1):3-50. DOI: https://doi.org/10.1002/ijgo.14116

Matsuzaki S, Lee M, Nagase Y, Jitsumori M, Matsuzaki S, Maeda M, et al. A systematic review and meta-analysis of obstetric and maternal outcomes after prior uterine artery embolization. Sci Rep. 2021;11(1):16914. DOI: https://doi.org/10.1038/s41598-021-96273-z

Kallianidis AF, Rijntjes D, Brobbel C, Dekkers OM, Bloemenkamp KWM, van den Akker T. Incidence, Indications, Risk Factors, and Outcomes of Emergency Peripartum Hysterectomy Worldwide: A Systematic Review and Meta-analysis. Obstet Gynecol. 2023;141(1):35. DOI: https://doi.org/10.1097/AOG.0000000000005022

Sihler KC, Napolitano LM. Complications of massive transfusion. Chest. 2010 ;137(1):209-20. DOI: https://doi.org/10.1378/chest.09-0252

Kogutt BK, Vaught AJ. Postpartum hemorrhage: Blood product management and massive transfusion. Semin Perinatol. 2019;43(1):44-50. DOI: https://doi.org/10.1053/j.semperi.2018.11.008

CDSCO. Recommendations of the SEC (Oncology and Haematology) made in its 155th meeting held on 24.08.2023 at CDSCO (HQ), New Delhi, CDSCO; 2023. Available at: https://cdsco.gov.in/opencms/ resources/UploadCDSCOWeb/2018/UploadCommitteeFiles/Recommendations%20Oncology%20%20Haematology%20dated%2024.08.2023.pdf. Accessed on 20 January 2025.

Novoseven India Pack Insert (4-51/Novo Nordisk/PAC-R-Eptacog alfa/2021-BD dated 21 Apr 2022) Updated on 22 Dec 2022. Available at: https://www.ema.europa.eu/en/documents/product-information/novoseven-epar-product-information_en.pdf?utm_source. Accessed on 20 January 2025.

NovoSeven European Medicines Agency (EMA). 2016. Available at: https://www.ema.europa.eu/ en/medicines/human/EPAR/novoseven. Accessed on 30 March 2025.

Hoffman M, Monroe DM. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Semin Hematol. 2001;38(4-12):6-9. DOI: https://doi.org/10.1016/S0037-1963(01)90140-4

Hawryluk GWJ, Cusimano MD. The role of recombinant activated factor VII in neurosurgery: hope or hype? J Neurosurg. 2006;105(6):859-68. DOI: https://doi.org/10.3171/jns.2006.105.6.859

Magon N, Babu K. Recombinant Factor VIIa in Post-partum Hemorrhage: A New Weapon in Obstetrician’s Armamentarium. N Am J Med Sci. 2012;4(4):157-62. DOI: https://doi.org/10.4103/1947-2714.94938

Alfirevic Z, Elbourne D, Pavord S, Bolte A, Van Geijn H, Mercier F, et al. Use of recombinant activated factor VII in primary postpartum hemorrhage: the Northern European registry 2000-2004. Obstet Gynecol. 2007;110(6):1270-8. DOI: https://doi.org/10.1097/01.AOG.0000288515.48066.99

Lavigne-Lissalde G, Aya AG, Mercier FJ, Roger-Christoph S, Chauleur C, Morau E, et al. Recombinant human FVIIa for reducing the need for invasive second-line therapies in severe refractory postpartum hemorrhage: a multicenter, randomized, open controlled trial. J Thromb Haemost. 2015;13(4):520-9. DOI: https://doi.org/10.1111/jth.12844

Bouma LS, Bolte AC, van Geijn HP. Use of recombinant activated factor VII in massive postpartum haemorrhage. Eur J Obstet Gynecol Reprod Biol. 2008;137(2):172-7. DOI: https://doi.org/10.1016/j.ejogrb.2007.06.022

Salman N, Rafay A, Junaid R, Hanfi R, Sultana M, Hussain M. Use of Recombinant Activated Factor VII: Pakistani Experience of Managing Massive Obstetric Haemorrhage. Niger Med J. 2022;62(5):267-72.

Colucci G, Helsing K, Biasiutti FD, Raio L, Schmid P, Tsakiris DA, et al. Standardized Management Protocol in Severe Postpartum Hemorrhage: A Single-Center Study. Clin Appl Thromb Hemost. 2018;24(6):884-93. DOI: https://doi.org/10.1177/1076029618758956

Barillari G, Frigo MG, Casarotto M, Farnia A, Massè B, Wetzl R, et al. Use of recombinant activated factor VII in severe post-partum haemorrhage: data from the Italian Registry: a multicentric observational retrospective study. Thromb Res. 2009;124(6):e41-7. DOI: https://doi.org/10.1016/j.thromres.2009.08.018

Phillips LE, McLintock C, Pollock W, Gatt S, Popham P, Jankelowitz G, et al. Recombinant activated factor VII in obstetric hemorrhage: experiences from the Australian and New Zealand Haemostasis Registry. Anesth Analg. 2009;109(6):1908-15. DOI: https://doi.org/10.1213/ANE.0b013e3181c039e6

Huber AW, Raio L, Alberio L, Ghezzi F, Surbek DV. Recombinant human factor VIIa prevents hysterectomy in severe postpartum hemorrhage: single center study. J Perinat Med. 2011;40(1):43-9. DOI: https://doi.org/10.1515/JPM.2011.109

Kobayashi T, Nakabayashi M, Yoshioka A, Maeda M, Ikenoue T. Recombinant activated factor VII (rFVIIa/NovoSeven®) in the management of severe postpartum haemorrhage: initial report of a multicentre case series in Japan. Int J Hematol. 2012;95(1):57-63. DOI: https://doi.org/10.1007/s12185-011-0974-9

Singi SR, Fernandez E, Pandya ST, Badrinath HR. Recombinant factor VIIa: use in fatal post partum hemorrhage-Indian experience case series and review of literature. Indian J Hematol Blood Transfus. 2009;25(1):1-5. DOI: https://doi.org/10.1007/s12288-009-0001-y

Magon N, Babu KM, Kapur K, Chopra S, Joneja GS. Recombinant activated factor VII in post partum haemorrhage. Niger Med J. 2013;54(5):289-94. DOI: https://doi.org/10.4103/0300-1652.122328

Goel A, Nair SC, Viswabandya A, Masilamani VP, Rao SV, George A, et al. Preliminary experience with use of recombinant activated factor VII to control postpartum hemorrhage in acute fatty liver of pregnancy and other pregnancy-related liver disorders. Indian J Gastroenterol. 2013;32(4):268-71. DOI: https://doi.org/10.1007/s12664-013-0315-4

Arun AP, Verma S, Gandhi S, Jourwal A, Choudhary N, Noorani Z. Role of recombinant factor 7 in PPH: a new weapon in obstetrician’s armamentarium. Int J Reprod Contracept Obstetr Gynecol. 2024;13(12):3666-70. DOI: https://doi.org/10.18203/2320-1770.ijrcog20243602

Butwick AJ, Riley ET. Recombinant factor VIIa for life-threatening post-partum haemorrhage. Brit J Anaest. 2005;95(4):558. DOI: https://doi.org/10.1093/bja/aei594

Haynes J, Laffan M, Plaat F. Use of recombinant activated factor VII in massive obstetric haemorrhage. Int J Obstet Anesth. 2007;16(1):40-9. DOI: https://doi.org/10.1016/j.ijoa.2006.07.005

Zatta A, Mcquilten Z, Kandane-Rathnayake R, Isbister J, Dunkley S, Mcneil J, et al. The Australian and New Zealand Haemostasis Registry: ten years of data on off-licence use of recombinant activated factor VII. Blood Transfus. 2015;13(1):86-99.

Van der Bom JG, Mercier FJ, Bausch-Fluck D, Nordentoft M, Medici M, Abdul-Kadir R. Thromboembolic events in severe postpartum hemorrhage treated with recombinant activated factor VII: a systematic literature review and meta-analysis. Res Pract Thromb Haemost. 2024;8(5):102533. DOI: https://doi.org/10.1016/j.rpth.2024.102533

Caram-Deelder C, McKinnon Edwards H, Zdanowicz JA, van den Akker T, Birkegård C, Blatný J, et al. Efficacy and Safety Analyses of Recombinant Factor VIIa in Severe Post-Partum Hemorrhage. J Clin Med. 2024;13(9):2656. DOI: https://doi.org/10.3390/jcm13092656

FOGSI FOCUS update in the management of severe PPH and the role of rFVIIa. Science Integra. 2024. Available at: https://www.fogsi.org/wp-content/uploads/2024/11/FOGSI-FOCUS-Factor-VII-1.pdf. Accessed on 12 January 2025.